Racial medicine: Here to stay?

EMBO Reports

Volumn 7, Issue 3, 2006, Pages 246-249

  Weigmann, Katrin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GOVERNMENT REGULATION; HAPLOTYPE; HEALTH CARE POLICY; HEALTH STATUS; HEART FAILURE; HUMAN; HUMAN GENETICS; MEDICAL RESEARCH; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RACISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN COLOR;

CONTINENTAL POPULATION GROUPS; DELIVERY OF HEALTH CARE; EDUCATION, MEDICAL; GENOME, HUMAN; HABITS; HUMANS; INTERNATIONALITY; MEDICINE; PHARMACEUTICAL PREPARATIONS; PHYSICIANS; VARIATION (GENETICS);

EID: 33645777233     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/sj.embor.7400654     Document Type: Article

References (19)

1. Abbott A (2005) Genetic patent singles out Jewish women. Nature 436: 12
2. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P; International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437: 1299-1320
3. Bloche MG (2004) Race-based therapeutics. N Engl J Med 351: 2035-2037
4. Carlson CS, Eberle MA, Rieder MJ, Smith JD, Kruglyak L, Nickerson DA (2003) Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet 33: 518-521
5. Carson P, Ziesche S, Johnson G, Cohn JN (1999) Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5: 178-187
6. Cohn JN et al (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314: 1547-1552
7. Cohn JN et al (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303-310
8. Couzin J (2004) Consensus emerges on HapMap strategy. Science 304: 671-673
9. Duster T (2005) Race and reification in science. Science 307: 1050-1051
10. Kahn J (2004) How a drug becomes 'ethnic': Law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics 4: 1-46
11. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. J Am Med Assoc 279: 1200-1205
12. Lee SS (2003) Race, distributive justice and the promise of pharmacogenomics: Ethical considerations. Am J Pharmacogenomics 3: 385-392
13. Lee SS (2005) Racializing drug design: Implications of pharmacogenomics for health disparities. Am J Public Health 95: 2133-2138
14. Rotimi CN (2004) Are medical and nonmedical uses of large-scale genomic markers conflating genetics and 'race'? Nat Genet 36 (Suppl): S43-S47
15. Satel S (2002) I am a racially profiling doctor. The New York Times Magazine, May 5 http://www.nytimes.com/pages/magazine
16. Tate SK, Goldstein DB (2004) Will tomorrow's medicines work for everyone? Nat Genet 36 (Suppl): S34-S42
17. Taylor AL et al (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351: 2049-2057
18. Tishkoff SA, Kidd KK (2004) Implications of biogeography of human populations for 'race' and medicine. Nat Genet 36 (Suppl): S21-S27
19. Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG, Bradman N, Goldstein DB (2001) Population genetic structure of variable drug response. Nat Genet 29: 265-269